06622 ZHAOKE OPHTH-B
- 1.350
- 0.0000.00%
ZHAOKE OPHTH-B News
Zhaoke Ophthalmology-B (06622.HK): Latanoprost eye drops, Tafluprost eye drops, and Tafluprost nasal drops have been approved for marketing by the National Medical Products Administration.
On December 9, Gelonghui reported that Zhaoke Ophthalmology-B (06622.HK) announced that following the approval for marketing of Betamethasone Timolol Eye Drops and Bimatoprost Eye Drops, the company's glaucoma product portfolio has recently added three more pharmaceuticals (Latanoprost Eye Drops, Travoprost Eye Drops, and Travoprost Timolol Eye Drops) that have been approved for listing by the National Medical Products Administration ("NMPA"), equivalent to passing the consistency evaluation of generic drugs. These pharmaceuticals are all produced by the company. Together with Betamethasone Timolol Eye Drops and Bimatoprost Eye Drops, they constitute a comprehensive glaucoma product portfolio for managing intraocular pressure. The company believes its products...
Express News | Zhaoke Ophthalmology - Marketing Authorizations Obtained From Nmpa for Latanoprost Eye Drop, Travoprost Eye Drop, and Travoprost Timolol Eye Drop
Zhaoke Ophthalmology's Phase 3 Trial of Myopia Progression Drug Shows Positive Results
China Medical Ophthalmology-B (06622.HK): The positive top-line results of the two-year China Phase III clinical trial (CHINA CHAMP) for NVK002, used to treat deepening myopia in children.
Oct 23, Geelong Health | Medigen Eye Care-B (06622.HK) announced that the topline results of the two-year Phase III clinical trial ("China CHAMP") of NVK002 (one of the company's core products) were released. After two years of treatment, the analysis of this study shows that the NVK002 eye drop group (0.01% and 0.02% doses) had statistically significant differences in the main efficacy indicators compared to the placebo group, with NVK002 eye drop group being superior to the placebo group and showing dose dependence. Both doses of NVK002 demonstrated good safety and patient compliance.
Zhaoke Ophthalmology Completes Last Patient Visit for Trial of Macular Degeneration Drug
Chow's Ophthalmology-B (06622.HK): The final visit of the last patient in the TAB014 Phase III clinical trial was completed in China.
Glory9thdayTheMeanwhile,ZodiacEye-C(06622.HK)announced that TAB014(oneofthecompany'scorecandidateproperties)hascompletedthelastvisitforthelastpatientinPhaseIIIclinicaltrialfortreatingwet(neovascular)age-relatedmaculardegeneration('wAMD')onSeptember20,2024.Accordingtothedisclosure,TAB014PhaseIIIclinicaltrialisrandomized,double-blind,andnon-inferioritystudy.Theprimaryobjectiveofthestudyistoevaluate the best correction of the group receiving TAB014 treatment compared to the group receiving Lucentis treatment at week 52.
ZHAOKE OPHTH-B: 2024 Interim Report
Zhaoke Ophthalmology Glaucoma Eye Drops Get Marketing Approval; Shares Rise 3%
Chokesee Eye Care-B (06622.HK): Bemei Prostaglandin Eye Drops (Jingbeiqing) approved by the National Medical Products Administration for listing.
Gelonghui, September 20th | Mega Medical Ophthalmology-B (06622.HK) announced that the company's independently developed anti-glaucoma pharmaceutical Beimei Latanoprost Eye Drops (Crystal Bear Clear) has been approved for marketing by the National Medical Products Administration ("NMPA"). According to the disclosure, Beimei Latanoprost Eye Drops (Crystal Bear Clear) is China's first single-dose Latanoprost eye drops without preservatives, used to reduce intraocular pressure in patients with angle-closure glaucoma and high ocular pressure. This pharmaceutical does not contain preservatives, avoiding eye surface damage in glaucoma patients caused by long-term use of preservative-containing medications. At the same time, this medication also helps improve patients
Express News | Zhaoke Ophthalmology Ltd - Marketing Authorization for Bimatoprost Eye Drop (®) Obtained From Nmpa
Research and development innovation, business cultivation, international perspective, examining the value growth logic of Chaoke Ophthalmology (6622.HK).
Over the next two years, Zhaoke Ophthalmology may usher in a period of intensive performance outbreaks.
Understanding the midterm performance of Meitu Eye Care (06622.HK) in 2024 in one picture.
On August 29, MediLink-Bev(06622.HK) announced its 2024 interim performance. Specific performance details will be explained below with a chart.
ZHAOKE OPHTH-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024
MegaMedical-B (06622.HK) will hold a board of directors meeting on August 29 to approve the interim performance.
On August 16, Glorious Sun Ophthalmic (6622.HK) announced that the board of directors will hold a meeting on August 29, 2024 to approve the midterm performance of the company and its subsidiaries for the six months ending June 30, 2024 and to publish its announcement.
ZHAOKE OPHTH-B: NOTICE OF BOARD MEETING
Zhaoke Ophthalmology Expects Losses to Shrink in H1
Express News | Corrected-Zhaoke Ophthalmology H1 Net Income RMB -77 Million (Corrects Amount)
Megvii Ophthalmology-B (06622) issued a profit warning, expecting the mid-term loss to narrow by no more than 77 million yuan year on year.
Megain Medical Group-B (06622) has released an announcement stating that the board of directors expects the group to negotiate with the creditors and reach a debt restructuring agreement by June 30, 2024...
Express News | Zhaoke Ophthalmology - Expected Result Due to Decrease in Research and Development Expenses Associated With Nvk002 and Tab014, Among Others
Express News | Zhaoke Ophthalmology Sees Loss of No More Than RMB77 Mln for Six Months
No Data
